Core Insights - The company reported solid overall performance in Q3, with organic growth and operating margins meeting expectations [1] - Free cash flow generation was strong, achieving about 90% conversion [2] Growth Performance - The software business experienced significant growth, increasing by 20% [2] - The newborn screening business showed strong performance, growing in the high single digits globally [3] - The U.S. immunodiagnostics franchise continued to progress, with growth in the mid-teens during the quarter [3]